- Home
- BODI vs INKT Comparison
BODI vs INKT Comparison
Compare BODI & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BODI
- INKT
- Stock Information
- Founded
- BODI 1998
- INKT 2017
- Country
- BODI United States
- INKT United States
- Employees
- BODI N/A
- INKT N/A
- Industry
- BODI Industrial Machinery/Components
- INKT Medicinal Chemicals and Botanical Products
- Sector
- BODI Industrials
- INKT Health Care
- Exchange
- BODI Nasdaq
- INKT Nasdaq
- Market Cap
- BODI 25.4M
- INKT 28.8M
- IPO Year
- BODI N/A
- INKT 2021
- Fundamental
- Price
- BODI $4.01
- INKT $39.62
- Analyst Decision
- BODI Strong Buy
- INKT Strong Buy
- Analyst Count
- BODI 3
- INKT 2
- Target Price
- BODI $10.67
- INKT $37.50
- AVG Volume (30 Days)
- BODI 23.7K
- INKT 2.4M
- Earning Date
- BODI 08-05-2025
- INKT 08-12-2025
- Dividend Yield
- BODI N/A
- INKT N/A
- EPS Growth
- BODI N/A
- INKT N/A
- EPS
- BODI N/A
- INKT N/A
- Revenue
- BODI $371,113,000.00
- INKT N/A
- Revenue This Year
- BODI N/A
- INKT N/A
- Revenue Next Year
- BODI N/A
- INKT N/A
- P/E Ratio
- BODI N/A
- INKT N/A
- Revenue Growth
- BODI N/A
- INKT N/A
- 52 Week Low
- BODI $3.38
- INKT $4.56
- 52 Week High
- BODI $8.71
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- BODI 50.21
- INKT 69.01
- Support Level
- BODI $3.75
- INKT $6.80
- Resistance Level
- BODI $4.43
- INKT $76.00
- Average True Range (ATR)
- BODI 0.28
- INKT 4.65
- MACD
- BODI 0.03
- INKT 4.24
- Stochastic Oscillator
- BODI 53.31
- INKT 49.48
About BODI The Beachbody Company Inc. Class A Common Stock
The Beachbody Co Inc is a health and wellness platform providing fitness, nutrition and stress-reducing programs to its customers. The product offerings of the company include Digital Subscriptions, Nutritional Products, and Connected Fitness Products. It earns the majority of its revenue from the United States. The company operates and manages its business in one operating segment. Majority of revenue is through Digital.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.